How did Century Therapeutics' revenue and expenses trend in Q4 2024?

In Q4 2024, Century Therapeutics experienced a total revenue of $4.17 million and incurred significant expenses. The R&D expenses reached $29.38 million, while the General and Administrative (G&A) expenses were $7.76 million. The absence of sales and marketing expense data suggests a focus on research and development, with less allocation to sales and marketing activities during this period.

|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|IPSC|IPSC.O|Century Therapeutics|2024 Q1|2.3421E7|-5.935981364713442|185|
|IPSC|IPSC.O|Century Therapeutics|2024 Q2|2.722E7|19.769437233246798|185|
|IPSC|IPSC.O|Century Therapeutics|2024 Q3|2.7228E7|1.6425265044049575|185|
|IPSC|IPSC.O|Century Therapeutics|2024 Q4|2.9375E7|26.094608516483515|185|

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|Selling, General, and Administrative Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|IPSC|IPSC.O|Century Therapeutics|20240331|8743000|-1.7861154796674903|185|
|IPSC|IPSC.O|Century Therapeutics|20240630|8306000|0.9357151537246323|185|
|IPSC|IPSC.O|Century Therapeutics|20240930|8352000|-7.055419541509014|185|
|IPSC|IPSC.O|Century Therapeutics|20241231|7755000|-9.710094306671325|185|